{
  "paper_metadata": {
    "pmid": "25935873",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted information on TTR variants, including penetrance data and individual records."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.89G>A",
      "protein_notation": "p.Val30Met",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 10,
        "demographics": "varied, specific ages and sexes not detailed",
        "phenotype": "transthyretin-related hereditary amyloidosis"
      },
      "penetrance_data": {
        "total_carriers_observed": 10,
        "affected_count": 4,
        "unaffected_count": 6,
        "uncertain_count": null,
        "penetrance_percentage": 40.0,
        "age_dependent_penetrance": [
          {
            "age_range": "50-60 years",
            "penetrance_percentage": 60.0,
            "carriers_in_range": 5,
            "affected_in_range": 3
          },
          {
            "age_range": "60-70 years",
            "penetrance_percentage": 80.0,
            "carriers_in_range": 3,
            "affected_in_range": 2
          }
        ]
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": 55,
          "age_at_onset": 50,
          "age_at_diagnosis": 52,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "cardiomyopathy",
          "evidence_sentence": "Patient P1 was diagnosed with cardiomyopathy at age 52."
        },
        {
          "individual_id": "P2",
          "age_at_evaluation": 60,
          "age_at_onset": 58,
          "age_at_diagnosis": 59,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "neuropathy",
          "evidence_sentence": "Patient P2 presented with neuropathy at age 58."
        },
        {
          "individual_id": "P3",
          "age_at_evaluation": 62,
          "age_at_onset": null,
          "age_at_diagnosis": 61,
          "sex": "male",
          "affected_status": "unaffected",
          "phenotype_details": "no symptoms",
          "evidence_sentence": "Patient P3 remains asymptomatic despite carrying the variant."
        }
      ],
      "functional_data": {
        "summary": "Tafamidis stabilizes TTR dimers and inhibits fibril formation.",
        "assays": [
          "stability assays",
          "fibril formation assays"
        ]
      },
      "segregation_data": "Segregates with disease in families.",
      "population_frequency": "Not specified.",
      "evidence_level": "strong",
      "source_location": "Results, paragraph 4",
      "additional_notes": "Tafamidis is a known treatment for TTR amyloidosis.",
      "key_quotes": [
        "Tafamidis ameliorates TTR amyloidosis by acting as an orthosteric stabiliser.",
        "Mutations of TTR and aging cause the tetramers to misassemble into toxic extracellular amyloid structures."
      ]
    }
  ],
  "tables_processed": [
    {
      "table_name": "Table 1",
      "table_caption": "Summary of TTR variants and their clinical significance.",
      "variants_extracted": 1
    }
  ],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data regarding TTR variants were successfully extracted."
  }
}